{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.6","upperLimit":"38.9","value":"37.00"},{"groupId":"OG001","lowerLimit":"23.3","upperLimit":"44.3","value":"38.60"},{"groupId":"OG002","lowerLimit":"30.6","upperLimit":"56.5","value":"44.00"},{"groupId":"OG003","lowerLimit":"30.2","upperLimit":"45.9","value":"33.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received eribulin mesylate 1.1 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up 4 cycles, or until PD or unacceptable toxicity or DLT's.","id":"OG000","title":"Part A1: Eribulin Mesylate 1.1 mg/m^2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 8 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG001","title":"Part A1: Eribulin Mesylate 1.4 mg/m^2"},{"description":"Participants received eribulin mesylate 1.8 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 5 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG002","title":"Part A1: Eribulin Mesylate 1.8 mg/m^2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 2 cycles, or until PD or unacceptable toxicity or drug related DLT's for evaluation of PK.","id":"OG003","title":"Part A1: Eribulin Mesylate PK Expansion"}],"paramType":"MEDIAN","populationDescription":"The pharmacokinetic analysis set (PAS) included all participants who had sufficient PK data to derive at least one PK parameter. The PAS where data at specified timepoints was available.","reportingStatus":"POSTED","timeFrame":"Day 1 predose and at 10, 30 minutes, 1, 2, 4, 6, 24, 48, 72, 96 or 120 hours post-dose","title":"T1/2: Terminal Half-life for Eribulin Mesylate","type":"PRIMARY","unitOfMeasure":"hours"}